Gene-Tweaked Pig Heart Transplant Into Second Patient
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
MONDAY, Sept. 25, 2023 -- A second human patient has received a genetically altered pig heart as he battles the ravages of end-stage heart disease. The 58-year-old man, Lawrence Faucette, received the pig organ at the University of Maryland Medical Center in Baltimore. The medical team was the same one that performed the first pig transplant with another patient in January 2022.
"We are once again offering a dying patient a shot at a longer life, and we are incredibly grateful to Mr. Faucette for his bravery and willingness to help advance our knowledge of this field," Bartley Griffith, M.D., a professor of transplant surgery and clinical director of the Cardiac Xenotransplantation Program, said in a medical center news release. Griffith transplanted the pig heart into both the first and second patients.
Faucette had been deemed ineligible for a transplant with a human heart because of preexisting peripheral vascular disease and complications with internal bleeding. A 58-year-old father of two from Frederick, Maryland, Faucette is currently breathing on his own. His heart is functioning well without supportive devices. A 20-year Navy veteran, he was a lab technician at the National Institutes of Health before retiring. Without the transplant, he would almost certainly have died from heart failure.
The xenotransplant was approved on Sept. 15 by the U.S. Food and Drug Administration under its single patient investigational new drug "compassionate use" pathway. The pig heart was provided by United Therapeutics Corp., through its xenotransplantation subsidiary Revivicor, based in Blacksburg, Virginia. The company has funded a $22 million research program to test pig hearts from Revivicor in baboons.
The surgical team removed the pig heart on the day of the surgery and put it in what is called the XVIVO Heart Box, which preserved it. Ten gene edits were made in the donor pig. Those involved knocking out three genes in the pig that could be involved in rejection of pig organs in the human body and one that will help prevent excessive growth of pig heart tissue. In addition, six human genes responsible for immune acceptance of the pig heart were inserted into the genome of the pig.
Faucette is also being treated with conventional anti-rejection drugs and a novel antibody therapy. The latter is experimental. Called tegoprubart, it blocks CD154, a protein involved in immune system activation.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Large Language Models May Aid Emergency Department Triage
TUESDAY, May 14, 2024 -- Large language models (LLMs) could enhance emergency department triage workflows, according to a study published online May 7 in JAMA Network...
Neighborhood Inequity Tied to More People Living With Vision Difficulty, Blindness
TUESDAY, May 14, 2024 -- Residential measures of inequity are associated with a greater number of individuals living with vision difficulty and blindness (VDB), according to a...
Elite Running Tied to Longer Life Expectancy
TUESDAY, May 14, 2024 -- Sub-four-minute mile runners have greater longevity than the general population, with results dating back as far as the 1950s, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.